Thus, we established a simple score scale composed of serum CRP, IL-6 and TNF-α levels to estimate the risk for progressing to PsA among psoriasis vulgaris patients, and validated the scale internally and for a retrospective cohort. This evidence concerns the gene TNF and psoriasis vulgaris.